{‘She lacks zero expertise’: the American medical field prepares for Dr. Høeg's role at the Food and Drug Administration.

Given that America undertakes historic revisions to its vaccine recommendations, an unexpected name has emerged unexpectedly: Høeg, an American of Danish descent sports medicine doctor and public health researcher who initially gained attention by casting doubt on COVID-19 shots throughout the global health crisis and has concentrated on possible fatalities following Covid immunization in her short time at the US Food and Drug Administration (FDA).

Planned Changes to Childhood Immunization Schedule

Health officials planned to reveal major revisions to the childhood vaccine schedule recently, synchronizing the US with Denmark’s national calendar, according to reports – a major change that would put the US out of alignment with much of the world with insufficient data for public health gain. This reveal has been pushed back until the new year.

Instead of the top vaccines chief, Høeg is scheduled to present at the meeting. She was just designated acting director of the FDA’s drug evaluation center, the fifth appointee to lead the office this year.

A New Direction at the Regulatory Body

This interim role may indicate a closer partnership between the drug and vaccine centers as Høeg and Prasad solidify control at the regulatory agency – and it signals a renewed priority upon reevaluating long-standing vaccines at the FDA.

The new acting director has frequently advocated for halting specific pediatric vaccine recommendations in the US in order to be more like Denmark, a nation with universal health coverage and a citizenry approximately the population of the state of Wisconsin.

So far public appearances, she has kept her attention on vaccination policy – traditionally the responsibility of Prasad, director of the FDA’s vaccine center – instead of drug regulation.

Doubts Over Background

The appointee has little discernible experience in medication creation, regulation or administrative roles, which has been standard for previous leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the commissioner and the vaccine center since spring.

“She appears not to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in running a large organization. She has no expertise in industry regulation.”

Former commissioners of CBER would “be deeply familiar with laws and regulations and the underlying principles of drug development”, commented a former acting FDA commissioner. “Clearly, she doesn’t have the type of experience that prior appointees who headed the center have had.”

This division has an vast range of responsibilities at the agency, the former commissioner emphasized.

“The public just pays attention on the novel medication approvals, but the generic program clears numerous off-brand pharmaceuticals. There’s a biologic copycat branch, OTC medication office and other areas, and every single one have to be looked after,” Dr. Woodcock explained. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a major administrative aspect to the job, which supervises over 5,000 personnel. “It is a huge administrative position, if you perform it correctly,” Woodcock concluded.

Response and Contentious Initiatives

Regarding concerns about Dr. Høeg's qualifications and whether this assignment indicates more teamwork among FDA leaders on vaccines, a representative stated that the “concerns stem from inaccurate presumptions”.

“Her resume aligns with the duties of her job,” the spokesperson said, noting the months Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and shot safety tracking”.

As the temporary head, Dr. Høeg takes over the commissioner’s new priority voucher program, a contentious rapid medication authorization process that reportedly worried her predecessors. “By what process are these medications being picked for this expedited pathway? Who takes the choices?” Dr. Howard said. “There is a lot of lack of transparency happening at the FDA right now.”

Overall, he stated, “the Food and Drug Administration seems to be moving towards more relaxed oversight of most medications, with the exception of immunizations.”

Documented Track Record on Immunizations

Concerning immunizations, Høeg has a more documented, if problematic, past, critics said. She published a analysis using non-validated public submissions to assess the frequency of myocarditis following Covid immunization. She counseled the state of Florida chief medical officer Joseph Ladapo, who was said to have modified findings to suggest COVID-19 vaccinations are more dangerous than they are.

Included in her “policy goals” for the incoming administration featured changing rules for novel immunizations and ending “non-essential” immunizations, she said following the vote on a podcast. At the agency, Høeg has according to sources suggested preventing adolescent males from obtaining COVID-19 vaccines.

“She is an complete ideologue who commences with her beliefs and works backwards to fit the data in a extremely misleading, untruthful way,” Dr. Howard argued.

Consolidating Power and a “Campaign of Retribution”

Høeg aligned with fellow skeptics, {like|